Premium
A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome
Author(s) -
Stevinson Clare,
Ernst Edzard
Publication year - 2000
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.2000.tb11085.x
Subject(s) - medicine , observational study , hypericum , hypericum perforatum , premenstrual dysphoric disorder , placebo , population , depression (economics) , randomized controlled trial , clinical trial , anxiety , physical therapy , psychiatry , menstrual cycle , traditional medicine , alternative medicine , pathology , hormone , macroeconomics , economics , environmental health
Objective To investigate whether Hypericum perforatum could relieve symptoms of premenstrual syndrome in a small group of women in order to establish a hypothesis and to test methods for conducting a future randomised controlled trial. Design Prospective, open, uncontrolled, observational study. Setting Department of Complementary Medicine, University of Exeter. Population Nineteen women with premenstrual syndrome who were in otherwise good physical and mental health and not taking other treatments for premenstrual syndrome. Method Volunteers underwent a preliminary screening interview, completed Daily Symptom Ratings for one cycle, and attended a medical screening visit before being diagnosed with premenstrual syndrome. Participants took hypericum tablets for two complete menstrual cycles (1 × 300 mg hypericum extract per day standardised to 900 μg hypericin). Main outcome measures Symptoms were rated daily throughout the trial using a validated measure. The Hospital Anxiety and Depression scale and modified Social Adjustment Scale were administered at baseline and after one and two cycles of treatment. Results There were significant reductions in all outcome measures. The degree of improvement in overall premenstrual syndrome scores between baseline and the end of the trial was 51%, with over two thirds of the sample demonstrating at least a 50% decrease in symptom severity. Tolerance and compliance with the treatment were encouraging. Conclusion The results of this pilot study suggest that there is scope for conducting a randomised, placebo‐controlled, double‐blind trial to investigate the value of hypericum as a treatment for premenstrual syndrome.